SCHEMBL15919083

SCHEMBL15919083

CCOC(=O)C1OCCc2cc(Br)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.43
KMT2A Q03164 5/20 0.42
MEN1 O00255 4/20 0.42
POLB P06746 1/20 0.42
TDP2 O95551 1/20 0.42
MAPK1 P28482 2/20 0.38
BCL2 P10415 1/20 0.37
ALDH1A1 P00352 4/20 0.37
FPR2 P25090 1/20 0.37
TP53 P04637 2/20 0.36
CAMK2A Q9UQM7 1/20 0.36
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
TSHR P16473 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 2/20 0.36
HTT P42858 1/20 0.36
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31730735 0.85 RAB9A (0.48) RAB9AKMT2AMEN1MAPK1ALDH1A1
SCHEMBL27267866 0.82 RAB9A (0.37) RAB9AKMT2AMEN1POLBALDH1A1
SCHEMBL27267803 0.81 RAB9A (0.36) RAB9AKMT2AMEN1ALDH1A1CYP4F2
SCHEMBL27267865 0.81 RAB9A (0.36) RAB9AKMT2AMEN1POLBMAPK1
SCHEMBL21688271 0.81 RAB9A (0.52) RAB9AKMT2AMEN1MAPK1ALDH1A1
SCHEMBL15912427 0.81 RAB9A (0.48) RAB9AKMT2AMAPK1ALDH1A1CAMK2A
SCHEMBL5098858 0.80 MAPT (0.41) KMT2AMEN1POLBTDP2ALDH1A1
SCHEMBL23286931 0.79 RAB9A (0.49) RAB9AKMT2AMEN1POLBMAPK1
SCHEMBL29960462 0.79 TP53 (0.40) KMT2AMEN1POLBMAPK1ALDH1A1
SCHEMBL15919087 0.78 ROCK1 (0.36) RAB9AKMT2AMAPK1ALDH1A1CYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024071439-A1 FUSED RING COMPOUND AND PHARMACEUTICAL CONTAINING SAME 科研製薬株式会社 2024-04-04 WO disclosed
US-20140213538-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. 2014-07-31 US disclosed
US-20140200215-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. 2014-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213538-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 RAB9A 2005/4885KMT2A 2450/4885MEN1 1384/4885
US-20140200215-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 RAB9A 2005/4885KMT2A 2450/4885MEN1 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.